In his weekly clinical update Dr. Griffin discusses Dr. Griffin discusses progress toward poliomyelitis eradication in Afghanistan, reduced risk for Mpox after receipt of 1 or 2 doses of JYNNEOS vaccine compared with risk among unvaccinated persons, reduced airborne transmission of SARS-CoV-2 BA.1 Omicron virus in Syrian hamsters, authorized updated (Bivalent) COVID-19 vaccines for children down to 6 months of age, low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by parental mRNA vaccine or a BA.5-bivalent booster, efficacy of antiviral agents against omicron subvariants BQ.1.1 and XBB, incidence of viral rebound after treatment with Nirmatrelvir-Ritonavir and Molnupiravir, and the effectiveness of coronavirus disease 2019 (COVID-19) vaccine in the prevention of post–COVID-19 conditions.

Become a patron of TWiV!

Links for this episode

• Progress toward Poliomyelitis eradication in Afghanistan (CDC)
• Reduced risk for Mpox after receipt of 1 or 2 Doses of JYNNEOS vaccine (CDC)
• Reduced airborne transmission of BA.1 Omicron virus in Syrian hamsters (PLOS)
• Authorized bivalent vaccines for children down to 6 months of age (FDA)
• Low neutralization of BA.2.75.2, BQ.1.1, and XBB.1 by parental mRNA vaccine (Nature)
• Efficacy of antiviral agents against Omicron subvariants BQ.1.1 and XBB (NEJM)
• Viral rebound after treatment with Nirmatrelvir-Ritonavir and Molnupiravir (JAMA)
• Paxlovid patient eligbiliity screening checklist (FDA)
• Effectiveness of COVID-19 vaccines in prevention of post–infection conditions (ASHE)
• Contribute to our MicrobeTV fundraiser at PWB
• Dr. Griffin’s treatment guide (pdf)
• Letters read on TWiV 964
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv